The early diagnosis of parkinson's disease

No abstract is available for this paper.

• Publication year

  1998

• Venue

  Annals of Neurology

• Publication date

  1998-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/ana.410440704PMID 9749569
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• PET studies of dopamine receptor distribution using [18F]fluoroethylspiperone: findings in disorders related to the dopaminergic system

  2005cited by this paper
• Pathology of Parkinsonism

  2000cited by this paper
• Genetic aspects of Parkinson's disease

  1998cited by this paper
• Measuring the rate of progression and estimating the preclinical period of Parkinson’s disease with [18F]dopa PET

  1998cited by this paper
• NAT2 slow acetylator phenotype is associated with familial Parkinson's disease

  1997cited by this paper
• Association of slow acetylator genotype for N-acetyltransferase 2 with familial Parkinson's disease.

  1997cited by this paper
• Genetic complexity and Parkinson's disease.

  1997cited by this paper
• Mutation in the alpha-synuclein gene identified in families with Parkinson's disease.

  1997cited by this paper
• Dopaminergic function in familial Parkinson's disease: A clinical and 18F‐dopa positron emission tomography study

  1997cited by this paper
• Relationship between clinical features of Parkinson's disease and presynaptic dopamine transporter binding assessed with [123I]IPT and single-photon emission tomography

  1997cited by this paper
• [11C]RTI‐32 PET studies of the dopamine transporter in early dopa‐naive Parkinson's disease

  1997cited by this paper
• Proton magnetic resonance spectroscopy in steele‐richardson‐olszewski syndrome

  1997cited by this paper
• An [18F]dopa-PET and clinical study of the rate of progression in Parkinson's disease.

  1996cited by this paper
• [123I] beta-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease.

  1996cited by this paper
• Comparative nigrostriatal dopaminergic imaging with iodine-123-beta CIT-FP/SPECT and fluorine-18-FDOPA/PET.

  1996cited by this paper
• Clinical and [18F] dopa PET findings in early Parkinson's disease.

  1995cited by this paper
• Decreased single‐photon emission computed tomographic {123I}β‐CIT striatal uptake correlates with symptom severity in parkinson's disease

  1995cited by this paper
• Differentiation of multiple system atrophy from idiopathic Parkinson's disease using proton magnetic resonance spectroscopy

  1995cited by this paper
• Differential diagnosis of Parkinson's disease, multiple system atrophy, and Steele-Richardson-Olszewski syndrome: discriminant analysis of striatal 18F-dopa PET data.

  1994cited by this paper
• Longitudinal fluorodopa positron emission tomographic studies of the evolution of idiopathic parkinsonism

  1994cited by this paper
• Olfactory testing differentiates between progressive supranuclear palsy and idiopathic Parkinson's disease

  1993cited by this paper
• Human positron emission tomographic [18F]Fluorodopa studies correlate with dopamine cell counts and levels

  1993cited by this paper
• Striatal hypometabolism distinguishes striatonigral degeneration from Parkinson's disease

  1993cited by this paper
• Dopamine D1 receptors in Parkinson's disease and striatonigral degeneration: a positron emission tomography study.

  1993cited by this paper
• Positron emission tomographic imaging of the dopamine transporter with 11C‐WIN 35,428 reveals marked declines in mild Parkinson's disease

  1993cited by this paper
• Parkinson's disease in twins studied with 18F‐dopa and positron emission tomography

  1992cited by this paper
• 123I‐iodobenzamide‐SPECT predicts dopaminergic responsiveness in patients with de novo parkinsonism

  1992cited by this paper
• Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.

  1992cited by this paper
• Fronto-striatal cognitive deficits at different stages of Parkinson's disease.

  1992cited by this paper
• Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C‐raclopride and positron emission tomography

  1992cited by this paper
• What features improve the accuracy of clinical diagnosis in Parkinson's disease

  1992cited by this paper
• Ageing and Parkinson's disease: substantia nigra regional selectivity.

  1991cited by this paper
• Striatal blood flow, glucose metabolism and 18F-dopa uptake: difference in Parkinson's disease and atypical parkinsonism.

  1991cited by this paper
• Xenobiotic enzyme profiles and Parkinson's disease

  1991cited by this paper
• Positron emission tomography in progressive supranuclear palsy.

  1991cited by this paper
• Electrophysiologic analysis of early Parkinson's disease

  1991cited by this paper
• Accuracy of Clinical Diagnosis in Parkinsonism — A Prospective Study

  1991cited by this paper
• The relationship between locomotor disability, autonomic dysfunction, and the integrity of the striatal dopaminergic system in patients with multiple system atrophy, pure autonomic failure, and Parkinson's disease, studied with PET.

  1990cited by this paper
• Differing patterns of striatal 18F‐dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy

  1990cited by this paper
• A Two-Compartment Description and Kinetic Procedure for Measuring Regional Cerebral [11C]Nomifensine Uptake Using Positron Emission Tomography

  1990cited by this paper
• The nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteer subjects and patients with Parkinson's disease.

  1990cited by this paper
• Striatonigral degeneration. A clinicopathological study.

  1990cited by this paper
• Striatal kinetics of [11C]‐(+)‐nomifensine and 6‐[18F]fluoro‐L‐dopa in Parkinson's disease measured with positron emission tomography

  1990cited by this paper
• Positron emission tomography study in progressive supranuclear palsy. Brain hypometabolic pattern and clinicometabolic correlations.

  1990cited by this paper
• Decreased glucose utilization in the striatum and frontal lobe in probable striatonigral degeneration

  1989cited by this paper
• Abnormalities of the electron transport chain in idiopathic parkinson's disease

  1989cited by this paper
• Multiple system atrophy--the nature of the beast.

  1989cited by this paper
• Dementia in Parkinson's disease is related to neuronal loss in the medial substantia nigra

  1989cited by this paper
• Positron tomography demonstrates frontal lobe hypometabolism in progressive supranuclear palsy

  1989cited by this paper
• Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications.

  1988cited by this paper
• Cerebral hypometabolism in progressive supranuclear palsy studied with positron emission tomography

  1988cited by this paper
• Planning and spatial working memory in Parkinson's disease.

  1988cited by this paper
• Steele-Richardson-Olszewski syndrome. Brain energy metabolism, blood flow and fluorodopa uptake measured by positron emission tomography.

  1988cited by this paper
• Disturbance of sequential movements in patients with Parkinson's disease.

  1987cited by this paper
• Cerebral Metabolism of 6–[18F]Fluoro‐l‐3,4‐Dihydroxyphenylalanine in the Primate

  1987influential reference
• Brain dopamine metabolism in patients with Parkinson's disease measured with positron emission tomography.

  1986cited by this paper
• Loss of Striatal [76Br]Bromospiperone Binding Sites Demonstrated by Positron Tomography in Progressive Supranuclear Palsy

  1986cited by this paper
• Subcortical dementia. Frontal cortex hypometabolism detected by positron tomography in patients with progressive supranuclear palsy.

  1985cited by this paper
• Striatal dopamine distribution in parkinsonian patients during life.

  1985cited by this paper
• Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.

  1973cited by this paper

• Multi-omics machine learning classifier and blood transcriptomic signature of Parkinson’s disease

  2025cites this paper
• Speech signal-based accurate neurological disorders detection using convolutional neural network and recurrent neural network based deep network

  2025cites this paper
• Exosomal microRNAs in Parkinson’s disease: insights into biomarker potential and disease pathology

  2024cites this paper
• Gut Microbiota and Immune System Dynamics in Parkinson’s and Alzheimer’s Diseases

  2024cites this paper
• Transcriptional pathobiology and multi-omics predictors for Parkinson’s disease

  2024cites this paper
• Long-term follow-up study of SWEDD patients with mild parkinsonian signs

  2024cites this paper
• Comparison of automated and manual quantification methods for neuromelanin‐sensitive MRI in Parkinson's disease

  2023cites this paper
• Endocytosis of GABA receptor: Signaling in nervous system.

  2023cites this paper
• Alpha-Synuclein mRNA Level Found Dependent on L444P Variant in Carriers and Gaucher Disease Patients on Enzyme Replacement Therapy

  2023cites this paper
• Revealing the neuroprotection and neurodegeneration efficacy of marine sponge extract in Parkinson's disease using gene expression and molecular docking

  2023cites this paper
• Newly Synthesized Creatine Derivatives as Potential Neuroprotective and Antioxidant Agents on In Vitro Models of Parkinson’s Disease

  2023cites this paper
• A sporadic Parkinson’s disease model via silencing of the ubiquitin–proteasome/E3 ligase component, SKP1A

  2023cites this paper
• Microbiome–gut–brain dysfunction in prodromal and symptomatic Lewy body diseases

  2022cites this paper
• Using IMU Sensors to Assess Motor Degradation of PD Patients by Modeling In-meal Plate-to-Mouth Movement Elongation

  2020cites this paper
• An in silico analysis of deleterious single nucleotide polymorphisms and molecular dynamics simulation of disease linked mutations in genes responsible for neurodegenerative disorder

  2020cites this paper
• Intrastriatal gradient analyses of 18F-FDOPA PET scans for differentiation of Parkinsonian disorders

  2020cites this paper
• Therapeutic Potential of Repeated Intravenous Transplantation of Human Adipose-Derived Stem Cells in Subchronic MPTP-Induced Parkinson’s Disease Mouse Model

  2020cites this paper
• Mitochondrial Signatures in Circulating Extracellular Vesicles of Older Adults with Parkinson’s Disease: Results from the EXosomes in PArkiNson’s Disease (EXPAND) Study

  2020cites this paper
• α-Synuclein Oligomer Detection with Aptamer Switch on Reduced Graphene Oxide Electrode

  2020cites this paper
• A deep learning approach for prediction of Parkinson’s disease progression

  2020cites this paper
• Deep Learning Identifies Digital Biomarkers for Self-Reported Parkinson's Disease

  2020cites this paper
• Peripheral Immunity, Immunoaging and Neuroinflammation in Parkinson's Disease.

  2019cites this paper
• Comparison of Reconstruction Algorithms for F-18 FP CIT PET Images

  2019cites this paper
• The Combination of DAT-SPECT, Structural and Diffusion MRI Predicts Clinical Progression in Parkinson’s Disease

  2019cites this paper
• Tandem Mass Spectrometric Analysis of Novel Caffeine Scaffold-Based Bifunctional Compounds for Parkinson's disease.

  2019cites this paper
• Association of olfaction dysfunction with brain microstructure in prodromal Parkinson disease

  2018cites this paper
• History and future challenges of the subthalamic nucleus as surgical target: Review article

  2018cites this paper
• Acetylcholine Neurotransmitter Receptor Densities in the Striatum of Hemiparkinsonian Rats Following Botulinum Neurotoxin-A Injection

  2018cites this paper
• Fractionally delineate the neuroprotective function of calbindin-D28k in Parkinson’s disease

  2018cites this paper
• Dopamine, Noradrenaline and Serotonin Receptor Densities in the Striatum of Hemiparkinsonian Rats following Botulinum Neurotoxin-A Injection.

  2018cites this paper
• [18F]FDOPA positron emission tomography in manganese‐exposed workers

  2017cites this paper
• Parkinson’s disease – the hardship at old age.

  2016cites this paper
• Neurorescue by a ROS Decomposition Catalyst.

  2016cites this paper
• Parkinson's Disease and Neurodegeneration: GABA-Collapse Hypothesis

  2016cites this paper
• Возможная патогенетическая роль грибковой инфекции при болезни Паркинсона и паркинсонизме = Fungal infection possible pathogenic role in Parkinson disease and parkinsonism

  2015cites this paper
• PET imaging of amyloid with Florbetapir F 18 and PET imaging of dopamine degeneration with 18F-AV-133 (florbenazine) in patients with Alzheimer’s disease and Lewy body disorders

  2014cites this paper
• Biophysical groundwork as a hinge to unravel the biology of α-synuclein aggregation and toxicity

  2014cites this paper
• Comparison of 99mTc-TRODAT-1 SPECT and 18 F-AV-133 PET imaging in healthy controls and Parkinson's disease patients.

  2014cites this paper
• Gastrodia elata Blume alleviates L-DOPA-induced dyskinesia by normalizing FosB and ERK activation in a 6-OHDA-lesioned Parkinson’s disease mouse model

  2014cites this paper
• Glutamate as a Neurotoxin

  2014cites this paper
• Role of the Innate and Adaptive Immune System in the Pathogenesis of PD

  2014cites this paper
• The Role of Innate and Adaptive Immunity in Parkinson's Disease

  2013cites this paper
• Use of PET in Neurology and Psychiatry

  2013cites this paper
• Diagnostic Value of the Impairment of Olfaction in Parkinson's Disease

  2013cites this paper
• The significance of defining preclinical or prodromal Parkinson's disease

  2012cites this paper
• Применение технологий ядерной медицины в неврологии, психиатрии и нейрохирургии

  2012cites this paper
• Gene Therapy for Parkinson's Disease

  2012cites this paper
• Dopamine Transporter Imaging for Distinguishing Between Idiopathic Parkinson’s Disease and Secondary Parkinsonism

  2012cites this paper
• Comparison of LEP and QST and their contribution to standard sensory diagnostic assessment of spinal lesions: a pilot study

  2011cites this paper
• Pre-motor signs of PD are related to SN hyperechogenicity assessed by TCS in an elderly population.

  2011cites this paper
• Preservation of function in Parkinson's disease: what's learning got to do with it?

  2011cites this paper
• Enhanced catecholamine transporter binding in the locus coeruleus of patients with early Parkinson disease

  2011cites this paper
• Relation of risk factors and putative premotor markers for Parkinson’s disease

  2011cites this paper
• Reduced uptake of [18F]FDOPA PET in asymptomatic welders with occupational manganese exposure

  2011cites this paper
• The status of olfactory function and the striatal dopaminergic system in drug-induced parkinsonism

  2010cites this paper
• In vivo evidence for long-term CNS toxicity, associated with chronic binge use of methamphetamine.

  2010cites this paper
• Pilot study: peripheral biomarkers for diagnosing sporadic Parkinson’s disease

  2010cites this paper
• (18)F-AV-133: A Selective VMAT2-binding Radiopharmaceutical for PET Imaging of Dopaminergic Neurons.

  2010cites this paper
• Clinical trials of disease-modifying therapies for neurodegenerative diseases: the challenges and the future

  2010cites this paper
• Macrophage-mediated GDNF delivery protects against dopaminergic neurodegeneration: a therapeutic strategy for Parkinson's disease.

  2010cites this paper
• The putative neuroprotective role of dopamine agonists in parkinson’s disease

  2009cites this paper
• Treating neuroinflammation: Exploring its potential in Parkinson's disease

  2009cites this paper
• Intake of tomato-enriched diet protects from 6-hydroxydopamine-induced degeneration of rat nigral dopaminergic neurons.

  2009cites this paper
• Neuroprotection in Parkinson's disease.

  2009cites this paper
• α-Synuclein and neuronal cell death

  2009cites this paper
• Disturbance of iron metabolism in Parkinson’s disease — ultrasonography as a biomarker

  2009cites this paper
• Dopamine‐dependent motor learning: Insight into levodopa's long‐duration response

  2009cites this paper
• The scientific and clinical basis for the treatment of Parkinson disease (2009)

  2009cites this paper
• Synthesis and evaluation of 2-amino-dihydrotetrabenzine derivatives as probes for imaging vesicular monoamine transporter-2.

  2009cites this paper
• Single-photon emission computed tomography and positron emission tomography evaluations of patients with central motor disorders.

  2008cites this paper
• STIMULATING AND ABLATIVE TREATMENT FOR PARKINSON'S DISEASE

  2008cites this paper
• Selective hyposmia and nigrostriatal dopaminergic denervation in Parkinson’s disease

  2007cites this paper
• Molecular imaging studies of the striatal dopaminergic system in psychosis and predictions for the prodromal phase of psychosis.

  2007cites this paper
• Disturbance of Iron Metabolism as a Contributing Factor to SN Hyperechogenicity in Parkinson’s Disease: Implications for Idiopathic and Monogenetic Forms

  2007cites this paper
• Magnetization transfer ratio in early period of Parkinson disease.

  2007cites this paper
• Patients with adult‐onset dystonic tremor resembling parkinsonian tremor have scans without evidence of dopaminergic deficit (SWEDDs)

  2007cites this paper
• Comparative anatomy of the hippocampal dentate gyrus in adult and developing rodents, non-human primates and humans.

  2007cites this paper
• Chapter 27 – Prevention and Therapy of Neurodegenerative Disorders: Role of Nutritional Antioxidants

  2007cites this paper
• Marker for a preclinical diagnosis of Parkinson's disease as a basis for neuroprotection.

  2006cites this paper
• Evaluation of basal ganglia haemodynamic changes with perfusion–weighted magnetic resonance imaging in patients with Parkinson’s disease

  2006cites this paper
• Fluoroalkyl derivatives of dihydrotetrabenazine as positron emission tomography imaging agents targeting vesicular monoamine transporters.

  2006cites this paper
• Role of Nutritional Antioxidants in the Prevention and Treatment of Neurodegenerative Disorders

  2006cites this paper
• dopaminergic degeneration in early stage Parkinson's disease

  2006cites this paper
• Growth hormone response in low-dose apomorphine test correlates with nigrostriatal dopamine transporter binding in patients with Parkinson’s disease

  2006cites this paper
• Lentivector‐mediated delivery of GDNF protects complex motor functions relevant to human Parkinsonism in a rat lesion model

  2005cites this paper
• Impaired acquisition of skilled behavior in rotarod task by moderate depletion of striatal dopamine in a pre-symptomatic stage model of Parkinson's disease.

  2005cites this paper
• Validation of the l-dopa-induced dyskinesia in the 6-OHDA model and evaluation of the effects of selective dopamine receptor agonists and antagonists.

  2005cites this paper
• Unique roles of SPET brain imaging in clinical and research studies. Lessons from Parkinson's disease research.

  2005cites this paper
• Neurodegenerative Diseases: Excitoxicity and excitatory amino acid antagonists in chronic neurodegenerative diseases

  2005cites this paper
• Positron Emission Tomography and Single-Photon Emission Tomography in the Diagnosis of Parkinson’s Disease

  2005cites this paper
• Brain SPECT imaging in multiple system atrophy

  2005cites this paper
• Rigidity and bradykinesia reduce interlimb coordination in Parkinsonian gait.

  2005cites this paper
• Charakterisierung 14-3-3zeta homologer Gene und deren Bedeutung für die Parkinson’sche Erkrankung

  2005cites this paper
• Cigarette smoking and Parkinson's disease: A case–control study in a population characterized by a high prevalence of pesticide exposure

  2005cites this paper
• HSV vector-delivery of GDNF in a rat model of PD: partial efficacy obscured by vector toxicity.

  2004cites this paper
• Cognitive and SPECT characteristics predict progression of Parkinson’s disease in newly diagnosed patients

  2004cites this paper
• Clinical Indications for Positron Emission Tomography (PET) Scanning

  2004cites this paper
• Effect of levodopa treatment for parkinsonism in welders: A double-blind study.

  2004cites this paper
• Manganese‐Induced Parkinsonism and Parkinson's Disease

  2004cites this paper
• Diagnostic issues in non-AD dementias

  2004cites this paper